Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics, Inc. (IPSC)
:IPSC
IPSC Stock Chart & Stats
$0.54
<$0.01(0.47%)
At close: 4:00 PM EST
$0.54
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.34 - $1.83
Previous CloseN/A
Volume712.78K
Average Volume (3M)1.33M
Market Cap
$41.24M
Enterprise Value-$44.73M
Total Cash (Recent Filing)$132.75M
Total Debt (Recent Filing)$44.96M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 12, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding87,307,090
10 Day Avg. Volume1,954,645
30 Day Avg. Volume1,333,579
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.49
Price to Sales (P/S)12.06
P/FCF Ratio-0.72
Enterprise Value/Market Cap-1.08
Enterprise Value/Revenue-0.39
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda3.15
Forecast
1Y Price Target
$4.50Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company reported $158.5M in cash, cash equivalents, and investments, expected to fund operations into 4Q27.
Innovative ProgramsCNTY-813 has been nominated as a new engineered iPSC-derived beta islet cell program with Allo-Evasion 5.0, currently in preclinical development for Type 1 diabetes.
Product RepurposingCNTY-101 is being repurposed in autoimmune disease based on its B-cell depletion profile, which management believes may mitigate prior risk.
Bears Say
Clinical Asset DowngradeThe company has been downgraded to Market Perform from Outperform due to the de-prioritization of their sole clinical asset.
Regulatory RisksRisks include failure to generate favorable clinical data from trials involving these candidates and inability to secure regulatory approval for investigational therapies, notably CNTY-101.
Trial Enrollment ChallengesEnrollment in the CALiPSO-1 trial is still lagging, with only two patients dosed as of 2Q.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.34 and its highest was $1.83 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $41.24M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is Mar 12, 2026 which is in 108 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.062.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.3.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 87,307,090 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -17.857%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
Century Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (733.33% Upside)
$4.50 (733.33% Upside)
Hedge Fund Trend
Decreased
By 241.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $801.9 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.53%
12-Months-Change
Fundamentals
Return on Equity
-14.23%
Trailing 12-Months
Asset Growth
-37.03%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics is a biotechnology company focused on developing and commercializing innovative cell therapies for the treatment of cancer. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, Century aims to create off-the-shelf, genetically engineered immune cell therapies that can be tailored for multiple cancer types. The company operates within the sectors of regenerative medicine and oncology, with core products centered around its iPSC-derived cell therapies designed to enhance the efficacy and accessibility of cancer treatments.
IPSC Stock 12 Month Forecast
Average Price Target
$4.50
▲(733.33% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
6.30% Insiders
2.89% Mutual Funds
10.49% Other Institutional Investors
78.23% Public Companies and
Individual Investors